Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Гиперурикемия и хроническая сердечная недостаточность: факторы риска и прогностические параллели
Гиперурикемия и хроническая сердечная недостаточность: факторы риска и прогностические параллели
Ларина В.Н., Ларин В.Г. Гиперурикемия и хроническая сердечная недостаточность: факторы риска и прогностические параллели. Consilium Medicum. 2020; 22 (5): 62–66. DOI: 10.26442/20751753.2020.5.200158
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Обоснование. Среди важнейших факторов риска сердечно-сосудистых заболеваний в последние годы рассматривают высокий уровень мочевой кислоты в сыворотке крови, однако сохраняется неоднозначной позиция относительно ассоциации гиперурикемии с рядом кардиометаболических состояний и хронической сердечной недостаточностью (ХСН).
Цель. Представить современные данные относительно причин гиперурикемии, ее ассоциации с ХСН и влияния на прогноз пациентов с данным синдромом.
Материалы и методы. Проанализированы отечественные и зарубежные рецензируемые литературные источники за последние 15 лет.
Результаты. Многие исследователи свидетельствуют о связи гиперурикеми с сердечно-сосудистыми заболеваниями, однако исследования с менделевской рандомизацией не показали убедительных доказательств этой связи. Изменения, происходящие в организме человека с момента выявления факторов риска до развития клинических симптомов заболеваний, могут быть как причиной гиперурикемии, так и ее последствием. Существующие данные свидетельствуют о развитии гемодинамических и метаболических изменений на фоне активации нейрогуморальных систем, что может лежать в основе тесной ассоциации гиперурикемии и сердечной недостаточности, в том числе и неблагоприятного течения последней.
Заключение. Гиперурикемия является компонентом сложных патофизиологических, гемодинамических и воспалительных процессов, в связи с чем важен контроль мочевой кислоты у всех пациентов с ХСН с целью своевременного выявления декомпенсации или прогрессирования заболевания.
Ключевые слова: фактор риска, мочевая кислота, гиперурикемия, сердечная недостаточность, прогноз.
Aim. To present data on the causes of hyperuricemia, its association with heart failure and the impact on the prognosis of patients with this syndrome.
Materials and methods. The search for publications in search systems over the past 15 years was done. The review includes articles from peer-reviewed literature.
Results. Many researchers have shown that hyperuricemia is associated with cardiovascular diseases, but studies with Mendelian randomization have not shown conclusive evidence of this association. Changes in the human body from the initiation of risk factors to the clinical symptoms can be both the cause of hyperuricemia and its consequence. Existing data indicate the development of hemodynamic and metabolic changes on the background of activation of neurohumoral systems, which may underlie the close association of hyperuricemia and heart failure, including the worse prognosis.
Conclusion. Hyperuricemia is a component of complex pathophysiological, hemodynamic and inflammatory processes, which is why uric acid control in all patients with heart failure is important in order to detect decompensation or disease progression in a timely manner.
Key words: risk factor, uric acid, hyperuricemia, heart failure, prognosis.
Цель. Представить современные данные относительно причин гиперурикемии, ее ассоциации с ХСН и влияния на прогноз пациентов с данным синдромом.
Материалы и методы. Проанализированы отечественные и зарубежные рецензируемые литературные источники за последние 15 лет.
Результаты. Многие исследователи свидетельствуют о связи гиперурикеми с сердечно-сосудистыми заболеваниями, однако исследования с менделевской рандомизацией не показали убедительных доказательств этой связи. Изменения, происходящие в организме человека с момента выявления факторов риска до развития клинических симптомов заболеваний, могут быть как причиной гиперурикемии, так и ее последствием. Существующие данные свидетельствуют о развитии гемодинамических и метаболических изменений на фоне активации нейрогуморальных систем, что может лежать в основе тесной ассоциации гиперурикемии и сердечной недостаточности, в том числе и неблагоприятного течения последней.
Заключение. Гиперурикемия является компонентом сложных патофизиологических, гемодинамических и воспалительных процессов, в связи с чем важен контроль мочевой кислоты у всех пациентов с ХСН с целью своевременного выявления декомпенсации или прогрессирования заболевания.
Ключевые слова: фактор риска, мочевая кислота, гиперурикемия, сердечная недостаточность, прогноз.
________________________________________________
Aim. To present data on the causes of hyperuricemia, its association with heart failure and the impact on the prognosis of patients with this syndrome.
Materials and methods. The search for publications in search systems over the past 15 years was done. The review includes articles from peer-reviewed literature.
Results. Many researchers have shown that hyperuricemia is associated with cardiovascular diseases, but studies with Mendelian randomization have not shown conclusive evidence of this association. Changes in the human body from the initiation of risk factors to the clinical symptoms can be both the cause of hyperuricemia and its consequence. Existing data indicate the development of hemodynamic and metabolic changes on the background of activation of neurohumoral systems, which may underlie the close association of hyperuricemia and heart failure, including the worse prognosis.
Conclusion. Hyperuricemia is a component of complex pathophysiological, hemodynamic and inflammatory processes, which is why uric acid control in all patients with heart failure is important in order to detect decompensation or disease progression in a timely manner.
Key words: risk factor, uric acid, hyperuricemia, heart failure, prognosis.
Полный текст
Список литературы
1. Чазова И.Е., Жернакова Ю.В., Кисляк О.А. и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском. Системные гипертензии. 2019; 16 (4): 8–21. DOI: 10.26442/2075082X.2019.4.190686
[Chazova I.E., Zhernakova Yu.V., Kislyak O.A. et al. Consensus on patients with hyperuricemia and high cardiovascular risk. Systemic Hypertension. 2019; 16 (4): 8–21. DOI: 10.26442/2075082X.2019.4.190686 (in Russian).]
2. Артериальная гипертензия у взрослых. Клинические рекомендации. Российское кардиологическое общество. Год утверждения 2020.
http://webmed.irkutsk.ru/doc/pdf/fedhypert.pdf
[Arterial'naia gipertenziia u vzroslykh. Klinicheskie rekomendatsii. Rossiiskoe kardiologicheskoe obshchestvo. God utverzhdeniia 2020. http://webmed.irkutsk.ru/doc/pdf/fedhypert.pdf (in Russian).]
3. Ventura HO, Stewart MH, Lavie CJ. New guidelines, increasing hypertension numbers, resistance and resistance to change. Mayo Clin Proc 2019; 94: 745–7.
4. Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и др. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018; 58 (6S): 8–158. DOI: 10.18087/cardio.2475
[Mareev V.Iu., Fomin I.V., Ageev F.T. et al. Klinicheskie rekomendatsii OSSN – RKO – RNMOT. Serdechnaia nedostatochnost': khronicheskaia (KhSN) i ostraia dekompensirovannaia (ODSN). Diagnostika, profilaktika i lechenie. Kardiologiia. 2018; 58 (6S): 8–158. DOI: 10.18087/cardio.2475 (in Russian).]
5. Li Q, Li X, Wang J et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open 2019; 9: e026677. DOI: 10.1136/ bmjopen-2018-026677
6. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 2014; 26 (2): 186–91. DOI: 10.1097/BOR.0000000000000028
7. Chalès G. How should we manage asymptomatic hyperuricemia? Joint Bone Spine 2019; 86 (4): 437–43.
8. Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology 2017; 56 (5): 679–88. DOI: 10.1093/rheumatology/kew293
9. Zoccali C, Maio R, Mallamaci F et al. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006; 17: 1466–71.
10. See L, Kuo C, Chuang F et al. Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate. J Rheumatol 2009; 36 (8): 1691–8.
11. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018; 39 (33): 3021–104. DOI: 10.1093/eurheartj/ehy339
12. Kei A, Koutsouka F, Makri A et al. Uric acid and cardiovascular risk: What genes can say. Int J Clin Pract 2018; 72: e13048.
13. Keenan T, Zhao W, Rasheed A et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol 2016; 67: 407–16.
14. Cho S, Chang Y, Kim I, Ryu S. U-shaped association between serum uric acid level and risk of mortality: a cohort study. Arthritis Rheumatol 2018; 70: 1122–32.
15. White J, Sofat R, Hemani G et al. UCLEB (University College London-London School of Hygiene & Tropical Medicine-Edinburgh-Bristol Consortium. Plasma urate concentration and risk of coronary heart disease: a Mendelian radomisation analysis. Lancet Diabetes Endocrinol 2016; 4 (4): 327–36. DOI: 10.1016/S22138587(15)00386-1
16. Kaufman M, Guglin M. Uric acid in heart failure: a biomarker or therapeutic target? Heart Fail Rev 2013; 18 (2): 177–86. DOI: 10.1007/s10741-012-9322-2
17. Doehner W, Springer J, Anker S. Uric acid in chronic heart failure – current pathophysiological consepts. Letter to the Editor. Eur J Heart Fail 2008; 10: 1269–70.
18. Zhang S, Cheng J, Huandfu N et al. Hyperuricemia and Cardiovascular Disease. Clin Pharm Des 2019; 25 (6): 700–9. DOI: 10.2174/1381612825666190408122557
19. Sun M, Vazquez A, Reynolds R et al. Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities. Arthritis Res Ther 2018, 20: 90.
20. Ochiai M, Baretto A, Oliveira M et al. Uric acid renal excretion and renal insufficiency in decompensated severe heart failure. Eur J Heart Fail 2005; 7: 468–74.
21. Ларина В.Н., Барт Б.Я., Ларин В.Г., Донсков А.С. Высокая концентрация сывороточной мочевой кислоты: клиническое и прогностическое значение при хронической сердечной недостаточности. Кардиология. 2016; 5: 68–75.
[Larina V.N., Bart B.Ia., Larin V.G., Donskov A.S. Vysokaia kontsentratsiia syvorotochnoi mochevoi kisloty: klinicheskoe i prognosticheskoe znachenie pri khronicheskoi serdechnoi nedostatochnosti. Kardiologiia. 2016; 5: 68–75 (in Russian).]
22. Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail 2009; 2 (6): 556–62.
23. Holme I, Aastveit A, Hammar N et al. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk Study (AMORIS). J Intern Med 2009; 266 (6): 558–70.
24. Krishnan E, Hariri A, Dabbous O et al. Hyperuricemia and the echocardiographic measures of myocardial dysfunction. Congest Heart Fail 2012; 18 (3): 138–43.
25. Huang H, Huang B, Li Y et al. Uric Acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail 2014; 16 (1): 15–24.
26. Cavarretta E, Frati G, Sciarretta S. Visit-to-Visit Systolic Blood Pressure Variability and Cardiovascular Outcomes: New Data From a Real-World Korean Population. Am J Hypertens 2017; 30: 550–3. DOI: 10.1093/ajh/hpx055
27. Bangalore S, Fayyad R, Laskey R et al. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med 2017; 376: 1332–40. DOI: 10.1056/NEJMoa1606148
28. Grossman C, Grossman E, Goldbourt U. Uric acid variability at midlife as an independent predictor of coronary heart disease and all-cause mortality. PLoS One 2019; 14 (8): e0220532. DOI: 10.1371/journal.pone.0220532
29. Filippatos G, Ahmed M, Gladden J et al. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J 2011;
32: 712–20.
30. Ogino K, Kato M, Furuse Y, Kinugasa Y. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail 2010; 3 (1): 73–81.
31. Ларина В.Н., Барт Б.Я., Вартанян Е.А. Факторы, влияющие на декомпенсацию хронической сердечной недостаточности у лиц пожилого возраста. Рациональная фармакотерапия в кардиологии. 2013; 9 (1): 15–24.
[Larina V.N., Bart B.Ia., Vartanian E.A. Faktory, vliiaiushchie na dekompensatsiiu khronicheskoi serdechnoi nedostatochnosti u lits pozhilogo vozrasta. Ratsional'naia farmakoterapiia v kardiologii. 2013; 9 (1): 15–24 (in Russian).]
32. Manzano L, Babalis D, Roughton M et al. Predictors of clinical outcomes in elderly patients with heart failure. Eur J Heart Fail 2011; 13: 528–36.
33. Alcaino H, Greig D, Chiong M et al. Serum acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 646–51.
34. Anker S, Doehner N, Raucchaus M et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional and hemodynamic staging. Circulation 2003; 107: 1991–7.
35. Ларина В.Н., Барт Б.Я., Бродский М.С. Клиническое и прогностическое значение гиперурикемии при хронической сердечной недостаточности у больных пожилого возраста. Журнал Сердечная Недостаточность. 2011; 5 (67): 277–81.
[Larina V.N., Bart B.Ia., Brodskii M.S. Klinicheskoe i prognosticheskoe znachenie giperurikemii pri khronicheskoi serdechnoi nedostatochnosti u bol'nykh pozhilogo vozrasta. Zhurnal Serdechnaia Nedostatochnost'. 2011; 5 (67): 277–81 (in Russian).]
2. Arterial'naia gipertenziia u vzroslykh. Klinicheskie rekomendatsii. Rossiiskoe kardiologicheskoe obshchestvo. God utverzhdeniia 2020. http://webmed.irkutsk.ru/doc/pdf/fedhypert.pdf (in Russian).
3. Ventura HO, Stewart MH, Lavie CJ. New guidelines, increasing hypertension numbers, resistance and resistance to change. Mayo Clin Proc 2019; 94: 745–7.
4. Mareev V.Iu., Fomin I.V., Ageev F.T. et al. Klinicheskie rekomendatsii OSSN – RKO – RNMOT. Serdechnaia nedostatochnost': khronicheskaia (KhSN) i ostraia dekompensirovannaia (ODSN). Diagnostika, profilaktika i lechenie. Kardiologiia. 2018; 58 (6S): 8–158. DOI: 10.18087/cardio.2475 (in Russian).
5. Li Q, Li X, Wang J et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open 2019; 9: e026677. DOI: 10.1136/ bmjopen-2018-026677
6. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 2014; 26 (2): 186–91. DOI: 10.1097/BOR.0000000000000028
7. Chalès G. How should we manage asymptomatic hyperuricemia? Joint Bone Spine 2019; 86 (4): 437–43.
8. Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology 2017; 56 (5): 679–88. DOI: 10.1093/rheumatology/kew293
9. Zoccali C, Maio R, Mallamaci F et al. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006; 17: 1466–71.
10. See L, Kuo C, Chuang F et al. Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate. J Rheumatol 2009; 36 (8): 1691–8.
11. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018; 39 (33): 3021–104. DOI: 10.1093/eurheartj/ehy339
12. Kei A, Koutsouka F, Makri A et al. Uric acid and cardiovascular risk: What genes can say. Int J Clin Pract 2018; 72: e13048.
13. Keenan T, Zhao W, Rasheed A et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol 2016; 67: 407–16.
14. Cho S, Chang Y, Kim I, Ryu S. U-shaped association between serum uric acid level and risk of mortality: a cohort study. Arthritis Rheumatol 2018; 70: 1122–32.
15. White J, Sofat R, Hemani G et al. UCLEB (University College London-London School of Hygiene & Tropical Medicine-Edinburgh-Bristol Consortium. Plasma urate concentration and risk of coronary heart disease: a Mendelian radomisation analysis. Lancet Diabetes Endocrinol 2016; 4 (4): 327–36. DOI: 10.1016/S22138587(15)00386-1
16. Kaufman M, Guglin M. Uric acid in heart failure: a biomarker or therapeutic target? Heart Fail Rev 2013; 18 (2): 177–86. DOI: 10.1007/s10741-012-9322-2
17. Doehner W, Springer J, Anker S. Uric acid in chronic heart failure – current pathophysiological consepts. Letter to the Editor. Eur J Heart Fail 2008; 10: 1269–70.
18. Zhang S, Cheng J, Huandfu N et al. Hyperuricemia and Cardiovascular Disease. Clin Pharm Des 2019; 25 (6): 700–9. DOI: 10.2174/1381612825666190408122557
19. Sun M, Vazquez A, Reynolds R et al. Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities. Arthritis Res Ther 2018, 20: 90.
20. Ochiai M, Baretto A, Oliveira M et al. Uric acid renal excretion and renal insufficiency in decompensated severe heart failure. Eur J Heart Fail 2005; 7: 468–74.
21. Larina V.N., Bart B.Ia., Larin V.G., Donskov A.S. Vysokaia kontsentratsiia syvorotochnoi mochevoi kisloty: klinicheskoe i prognosticheskoe znachenie pri khronicheskoi serdechnoi nedostatochnosti. Kardiologiia. 2016; 5: 68–75 (in Russian).
22. Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail 2009; 2 (6): 556–62.
23. Holme I, Aastveit A, Hammar N et al. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk Study (AMORIS). J Intern Med 2009; 266 (6): 558–70.
24. Krishnan E, Hariri A, Dabbous O et al. Hyperuricemia and the echocardiographic measures of myocardial dysfunction. Congest Heart Fail 2012; 18 (3): 138–43.
25. Huang H, Huang B, Li Y et al. Uric Acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail 2014; 16 (1): 15–24.
26. Cavarretta E, Frati G, Sciarretta S. Visit-to-Visit Systolic Blood Pressure Variability and Cardiovascular Outcomes: New Data From a Real-World Korean Population. Am J Hypertens 2017; 30: 550–3. DOI: 10.1093/ajh/hpx055
27. Bangalore S, Fayyad R, Laskey R et al. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med 2017; 376: 1332–40. DOI: 10.1056/NEJMoa1606148
28. Grossman C, Grossman E, Goldbourt U. Uric acid variability at midlife as an independent predictor of coronary heart disease and all-cause mortality. PLoS One 2019; 14 (8): e0220532. DOI: 10.1371/journal.pone.0220532
29. Filippatos G, Ahmed M, Gladden J et al. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J 2011;
32: 712–20.
30. Ogino K, Kato M, Furuse Y, Kinugasa Y. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail 2010; 3 (1): 73–81.
31. Larina V.N., Bart B.Ia., Vartanian E.A. Faktory, vliiaiushchie na dekompensatsiiu khronicheskoi serdechnoi nedostatochnosti u lits pozhilogo vozrasta. Ratsional'naia farmakoterapiia v kardiologii. 2013; 9 (1): 15–24 (in Russian).
32. Manzano L, Babalis D, Roughton M et al. Predictors of clinical outcomes in elderly patients with heart failure. Eur J Heart Fail 2011; 13: 528–36.
33. Alcaino H, Greig D, Chiong M et al. Serum acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 646–51.
34. Anker S, Doehner N, Raucchaus M et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional and hemodynamic staging. Circulation 2003; 107: 1991–7.
35. Larina V.N., Bart B.Ia., Brodskii M.S. Klinicheskoe i prognosticheskoe znachenie giperurikemii pri khronicheskoi serdechnoi nedostatochnosti u bol'nykh pozhilogo vozrasta. Zhurnal Serdechnaia Nedostatochnost'. 2011; 5 (67): 277–81 (in Russian).
[Chazova I.E., Zhernakova Yu.V., Kislyak O.A. et al. Consensus on patients with hyperuricemia and high cardiovascular risk. Systemic Hypertension. 2019; 16 (4): 8–21. DOI: 10.26442/2075082X.2019.4.190686 (in Russian).]
2. Артериальная гипертензия у взрослых. Клинические рекомендации. Российское кардиологическое общество. Год утверждения 2020.
http://webmed.irkutsk.ru/doc/pdf/fedhypert.pdf
[Arterial'naia gipertenziia u vzroslykh. Klinicheskie rekomendatsii. Rossiiskoe kardiologicheskoe obshchestvo. God utverzhdeniia 2020. http://webmed.irkutsk.ru/doc/pdf/fedhypert.pdf (in Russian).]
3. Ventura HO, Stewart MH, Lavie CJ. New guidelines, increasing hypertension numbers, resistance and resistance to change. Mayo Clin Proc 2019; 94: 745–7.
4. Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и др. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018; 58 (6S): 8–158. DOI: 10.18087/cardio.2475
[Mareev V.Iu., Fomin I.V., Ageev F.T. et al. Klinicheskie rekomendatsii OSSN – RKO – RNMOT. Serdechnaia nedostatochnost': khronicheskaia (KhSN) i ostraia dekompensirovannaia (ODSN). Diagnostika, profilaktika i lechenie. Kardiologiia. 2018; 58 (6S): 8–158. DOI: 10.18087/cardio.2475 (in Russian).]
5. Li Q, Li X, Wang J et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open 2019; 9: e026677. DOI: 10.1136/ bmjopen-2018-026677
6. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 2014; 26 (2): 186–91. DOI: 10.1097/BOR.0000000000000028
7. Chalès G. How should we manage asymptomatic hyperuricemia? Joint Bone Spine 2019; 86 (4): 437–43.
8. Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology 2017; 56 (5): 679–88. DOI: 10.1093/rheumatology/kew293
9. Zoccali C, Maio R, Mallamaci F et al. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006; 17: 1466–71.
10. See L, Kuo C, Chuang F et al. Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate. J Rheumatol 2009; 36 (8): 1691–8.
11. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018; 39 (33): 3021–104. DOI: 10.1093/eurheartj/ehy339
12. Kei A, Koutsouka F, Makri A et al. Uric acid and cardiovascular risk: What genes can say. Int J Clin Pract 2018; 72: e13048.
13. Keenan T, Zhao W, Rasheed A et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol 2016; 67: 407–16.
14. Cho S, Chang Y, Kim I, Ryu S. U-shaped association between serum uric acid level and risk of mortality: a cohort study. Arthritis Rheumatol 2018; 70: 1122–32.
15. White J, Sofat R, Hemani G et al. UCLEB (University College London-London School of Hygiene & Tropical Medicine-Edinburgh-Bristol Consortium. Plasma urate concentration and risk of coronary heart disease: a Mendelian radomisation analysis. Lancet Diabetes Endocrinol 2016; 4 (4): 327–36. DOI: 10.1016/S22138587(15)00386-1
16. Kaufman M, Guglin M. Uric acid in heart failure: a biomarker or therapeutic target? Heart Fail Rev 2013; 18 (2): 177–86. DOI: 10.1007/s10741-012-9322-2
17. Doehner W, Springer J, Anker S. Uric acid in chronic heart failure – current pathophysiological consepts. Letter to the Editor. Eur J Heart Fail 2008; 10: 1269–70.
18. Zhang S, Cheng J, Huandfu N et al. Hyperuricemia and Cardiovascular Disease. Clin Pharm Des 2019; 25 (6): 700–9. DOI: 10.2174/1381612825666190408122557
19. Sun M, Vazquez A, Reynolds R et al. Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities. Arthritis Res Ther 2018, 20: 90.
20. Ochiai M, Baretto A, Oliveira M et al. Uric acid renal excretion and renal insufficiency in decompensated severe heart failure. Eur J Heart Fail 2005; 7: 468–74.
21. Ларина В.Н., Барт Б.Я., Ларин В.Г., Донсков А.С. Высокая концентрация сывороточной мочевой кислоты: клиническое и прогностическое значение при хронической сердечной недостаточности. Кардиология. 2016; 5: 68–75.
[Larina V.N., Bart B.Ia., Larin V.G., Donskov A.S. Vysokaia kontsentratsiia syvorotochnoi mochevoi kisloty: klinicheskoe i prognosticheskoe znachenie pri khronicheskoi serdechnoi nedostatochnosti. Kardiologiia. 2016; 5: 68–75 (in Russian).]
22. Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail 2009; 2 (6): 556–62.
23. Holme I, Aastveit A, Hammar N et al. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk Study (AMORIS). J Intern Med 2009; 266 (6): 558–70.
24. Krishnan E, Hariri A, Dabbous O et al. Hyperuricemia and the echocardiographic measures of myocardial dysfunction. Congest Heart Fail 2012; 18 (3): 138–43.
25. Huang H, Huang B, Li Y et al. Uric Acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail 2014; 16 (1): 15–24.
26. Cavarretta E, Frati G, Sciarretta S. Visit-to-Visit Systolic Blood Pressure Variability and Cardiovascular Outcomes: New Data From a Real-World Korean Population. Am J Hypertens 2017; 30: 550–3. DOI: 10.1093/ajh/hpx055
27. Bangalore S, Fayyad R, Laskey R et al. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med 2017; 376: 1332–40. DOI: 10.1056/NEJMoa1606148
28. Grossman C, Grossman E, Goldbourt U. Uric acid variability at midlife as an independent predictor of coronary heart disease and all-cause mortality. PLoS One 2019; 14 (8): e0220532. DOI: 10.1371/journal.pone.0220532
29. Filippatos G, Ahmed M, Gladden J et al. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J 2011;
32: 712–20.
30. Ogino K, Kato M, Furuse Y, Kinugasa Y. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail 2010; 3 (1): 73–81.
31. Ларина В.Н., Барт Б.Я., Вартанян Е.А. Факторы, влияющие на декомпенсацию хронической сердечной недостаточности у лиц пожилого возраста. Рациональная фармакотерапия в кардиологии. 2013; 9 (1): 15–24.
[Larina V.N., Bart B.Ia., Vartanian E.A. Faktory, vliiaiushchie na dekompensatsiiu khronicheskoi serdechnoi nedostatochnosti u lits pozhilogo vozrasta. Ratsional'naia farmakoterapiia v kardiologii. 2013; 9 (1): 15–24 (in Russian).]
32. Manzano L, Babalis D, Roughton M et al. Predictors of clinical outcomes in elderly patients with heart failure. Eur J Heart Fail 2011; 13: 528–36.
33. Alcaino H, Greig D, Chiong M et al. Serum acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 646–51.
34. Anker S, Doehner N, Raucchaus M et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional and hemodynamic staging. Circulation 2003; 107: 1991–7.
35. Ларина В.Н., Барт Б.Я., Бродский М.С. Клиническое и прогностическое значение гиперурикемии при хронической сердечной недостаточности у больных пожилого возраста. Журнал Сердечная Недостаточность. 2011; 5 (67): 277–81.
[Larina V.N., Bart B.Ia., Brodskii M.S. Klinicheskoe i prognosticheskoe znachenie giperurikemii pri khronicheskoi serdechnoi nedostatochnosti u bol'nykh pozhilogo vozrasta. Zhurnal Serdechnaia Nedostatochnost'. 2011; 5 (67): 277–81 (in Russian).]
________________________________________________
2. Arterial'naia gipertenziia u vzroslykh. Klinicheskie rekomendatsii. Rossiiskoe kardiologicheskoe obshchestvo. God utverzhdeniia 2020. http://webmed.irkutsk.ru/doc/pdf/fedhypert.pdf (in Russian).
3. Ventura HO, Stewart MH, Lavie CJ. New guidelines, increasing hypertension numbers, resistance and resistance to change. Mayo Clin Proc 2019; 94: 745–7.
4. Mareev V.Iu., Fomin I.V., Ageev F.T. et al. Klinicheskie rekomendatsii OSSN – RKO – RNMOT. Serdechnaia nedostatochnost': khronicheskaia (KhSN) i ostraia dekompensirovannaia (ODSN). Diagnostika, profilaktika i lechenie. Kardiologiia. 2018; 58 (6S): 8–158. DOI: 10.18087/cardio.2475 (in Russian).
5. Li Q, Li X, Wang J et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open 2019; 9: e026677. DOI: 10.1136/ bmjopen-2018-026677
6. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 2014; 26 (2): 186–91. DOI: 10.1097/BOR.0000000000000028
7. Chalès G. How should we manage asymptomatic hyperuricemia? Joint Bone Spine 2019; 86 (4): 437–43.
8. Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology 2017; 56 (5): 679–88. DOI: 10.1093/rheumatology/kew293
9. Zoccali C, Maio R, Mallamaci F et al. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006; 17: 1466–71.
10. See L, Kuo C, Chuang F et al. Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate. J Rheumatol 2009; 36 (8): 1691–8.
11. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018; 39 (33): 3021–104. DOI: 10.1093/eurheartj/ehy339
12. Kei A, Koutsouka F, Makri A et al. Uric acid and cardiovascular risk: What genes can say. Int J Clin Pract 2018; 72: e13048.
13. Keenan T, Zhao W, Rasheed A et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol 2016; 67: 407–16.
14. Cho S, Chang Y, Kim I, Ryu S. U-shaped association between serum uric acid level and risk of mortality: a cohort study. Arthritis Rheumatol 2018; 70: 1122–32.
15. White J, Sofat R, Hemani G et al. UCLEB (University College London-London School of Hygiene & Tropical Medicine-Edinburgh-Bristol Consortium. Plasma urate concentration and risk of coronary heart disease: a Mendelian radomisation analysis. Lancet Diabetes Endocrinol 2016; 4 (4): 327–36. DOI: 10.1016/S22138587(15)00386-1
16. Kaufman M, Guglin M. Uric acid in heart failure: a biomarker or therapeutic target? Heart Fail Rev 2013; 18 (2): 177–86. DOI: 10.1007/s10741-012-9322-2
17. Doehner W, Springer J, Anker S. Uric acid in chronic heart failure – current pathophysiological consepts. Letter to the Editor. Eur J Heart Fail 2008; 10: 1269–70.
18. Zhang S, Cheng J, Huandfu N et al. Hyperuricemia and Cardiovascular Disease. Clin Pharm Des 2019; 25 (6): 700–9. DOI: 10.2174/1381612825666190408122557
19. Sun M, Vazquez A, Reynolds R et al. Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities. Arthritis Res Ther 2018, 20: 90.
20. Ochiai M, Baretto A, Oliveira M et al. Uric acid renal excretion and renal insufficiency in decompensated severe heart failure. Eur J Heart Fail 2005; 7: 468–74.
21. Larina V.N., Bart B.Ia., Larin V.G., Donskov A.S. Vysokaia kontsentratsiia syvorotochnoi mochevoi kisloty: klinicheskoe i prognosticheskoe znachenie pri khronicheskoi serdechnoi nedostatochnosti. Kardiologiia. 2016; 5: 68–75 (in Russian).
22. Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail 2009; 2 (6): 556–62.
23. Holme I, Aastveit A, Hammar N et al. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk Study (AMORIS). J Intern Med 2009; 266 (6): 558–70.
24. Krishnan E, Hariri A, Dabbous O et al. Hyperuricemia and the echocardiographic measures of myocardial dysfunction. Congest Heart Fail 2012; 18 (3): 138–43.
25. Huang H, Huang B, Li Y et al. Uric Acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail 2014; 16 (1): 15–24.
26. Cavarretta E, Frati G, Sciarretta S. Visit-to-Visit Systolic Blood Pressure Variability and Cardiovascular Outcomes: New Data From a Real-World Korean Population. Am J Hypertens 2017; 30: 550–3. DOI: 10.1093/ajh/hpx055
27. Bangalore S, Fayyad R, Laskey R et al. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med 2017; 376: 1332–40. DOI: 10.1056/NEJMoa1606148
28. Grossman C, Grossman E, Goldbourt U. Uric acid variability at midlife as an independent predictor of coronary heart disease and all-cause mortality. PLoS One 2019; 14 (8): e0220532. DOI: 10.1371/journal.pone.0220532
29. Filippatos G, Ahmed M, Gladden J et al. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J 2011;
32: 712–20.
30. Ogino K, Kato M, Furuse Y, Kinugasa Y. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail 2010; 3 (1): 73–81.
31. Larina V.N., Bart B.Ia., Vartanian E.A. Faktory, vliiaiushchie na dekompensatsiiu khronicheskoi serdechnoi nedostatochnosti u lits pozhilogo vozrasta. Ratsional'naia farmakoterapiia v kardiologii. 2013; 9 (1): 15–24 (in Russian).
32. Manzano L, Babalis D, Roughton M et al. Predictors of clinical outcomes in elderly patients with heart failure. Eur J Heart Fail 2011; 13: 528–36.
33. Alcaino H, Greig D, Chiong M et al. Serum acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 646–51.
34. Anker S, Doehner N, Raucchaus M et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional and hemodynamic staging. Circulation 2003; 107: 1991–7.
35. Larina V.N., Bart B.Ia., Brodskii M.S. Klinicheskoe i prognosticheskoe znachenie giperurikemii pri khronicheskoi serdechnoi nedostatochnosti u bol'nykh pozhilogo vozrasta. Zhurnal Serdechnaia Nedostatochnost'. 2011; 5 (67): 277–81 (in Russian).
Авторы
В.Н. Ларина*, В.Г. Ларин
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия
*larinav@mail.ru
Pirogov Russian National Research Medical University, Moscow, Russia
*larinav@mail.ru
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия
*larinav@mail.ru
________________________________________________
Pirogov Russian National Research Medical University, Moscow, Russia
*larinav@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.